Department of Radiology
Found 9 results
Filters: Keyword is Prostate-Specific Antigen  [Clear All Filters]
2023
Yun H, Kim J, Gandhe A, Nelson B, Hu JC, Gulani V, Margolis D, Schackman BR, Jalali A.  2023.  Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.. JAMA Netw Open. 6(11):e2344856.
Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L et al..  2023.  Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).. Eur J Nucl Med Mol Imaging. 50(9):2830-2845.
Stangl-Kremser J, Sun M, Ho B, Thomas J, Nauseef JT, Osborne JR, Molina A, Sternberg CN, Nanus DM, Bander NH et al..  2023.  Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.. Prostate. 83(14):1351-1357.
Stangl-Kremser J, Ricaurte-Fajardo A, Subramanian K, Osborne JR, Sun M, Tagawa ST, Bander NH.  2023.  Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.. Prostate. 83(10):901-911.
Hope TA, Antonarakis ES, Bodei L, Calais J, Iravani A, Jacene H, Koo PJ, Morgans AK, Osborne JR, Tagawa ST et al..  2023.  SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy.. J Nucl Med. 64(9):1417-1423.
2020
Kelly JM, Ponnala S, Amor-Coarasa A, Zia NA, Nikolopoulou A, Williams C, Schlyer DJ, DiMagno SG, Donnelly PS, Babich JW.  2020.  Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for Cu/Cu-Based Theranostics in Prostate Cancer.. Mol Pharm. 17(6):1954-1962.
2018
Patel N, Cricco-Lizza E, Kasabwala K, Xu C, Robinson BD, Khani F, Wang Y, Margolis D, Hu JC.  2018.  The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy.. Eur Urol Oncol. 1(4):263-267.
2004
Pucar D, Koutcher JA, Shah A, Dyke JP, Schwartz L, Thaler H, Kurhanewicz J, Scardino PT, W Kelly K, Hricak H et al..  2004.  Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse.. Clin Prostate Cancer. 3(3):174-81.
2003
Dyke JP, Zakian KL, Spees WM, Matei C, Chen Y, Mao X, Shungu DC, Koutcher JA.  2003.  Metabolic response of the CWR22 prostate tumor xenograft after 20 Gy of radiation studied by 1H spectroscopic imaging.. Clin Cancer Res. 9(12):4529-36.